An IATA sampling of costs for PCR tests (the test most frequently required by governments) in 16 countries showed wide variations by markets and within markets. Findings include:
- Of the markets surveyed, only France complied with the World Health Organization (WHO) recommendation for the state to bear the cost of testing for travelers
- Of the 15 markets where there is a cost for PCR testing to the individual
- The average minimum cost for testing was $90.
- The average maximum cost for testing was $208.
Even taking the average of the low-end cost, adding PCR testing to airfares would dramatically increase the cost of flying for individuals. Pre-crisis, the average one-way airline ticket, including taxes and charges, cost $200 (2019 data). A $90 PCR test raises the cost 45% to $290. Add another test on arrival and the one-way cost would leap 90% to $380. Assuming that two tests are needed in each direction, the average cost for an individual return-trip could balloon from $400 to $760.
The impact of the costs of COVID-19 testing on family travel would be even more severe. Based on average ticket prices ($200) and average low-end PCR testing ($90) twice each way, a journey for four that would have cost $1,600 pre-COVID, could nearly double to $3,040—with $1,440 being testing costs.
“As travel restrictions are lifted in domestic markets, we are seeing strong demand,” said Willie Walsh, IATA’s Director General. “The same can be expected in international markets. But that could be perilously compromised by testing costs—particularly PCR testing. Raising the cost of any product this significantly will stifle demand. The impact will be greatest for short haul trips (up to 1,100 km), with average fares of $105, the tests will cost more than the flight. That’s not what you want to propose to travelers as we emerge from this crisis. Testing costs must be better managed. That’s critical if governments want to save tourism and transport jobs; and avoid limiting travel freedoms to the wealthy.”
WHO International Health Regulations stipulate that states should not charge for testing or vaccination required for travel, or for the issuance of certificates. The WHO COVID Emergency Committee recently reiterated this position, calling on governments to reduce the financial burden on international travelers of complying with testing requirements and any other public health measures implemented by countries.
“Testing costs should not stand between people and their freedom to travel,” said Walsh. “The best solution is for the costs to be borne by governments. It’s their responsibility under WHO guidelines. We must not let the cost of testing—particularly PCR testing—limit the freedom to travel to the rich or those able to be vaccinated. A successful restart of travel means so much to people—from personal job security to business opportunities and the need to see family and friends. Governments must act quickly to ensure that testing costs don’t stall a travel recovery.”